-
Ther Adv Med Oncol: Real-World Data Study of Treatment and Prognosis in Young (≤40 Years) Patients with Newly Diagnosed Metastatic Female Breast Cancer
Time of Update: 2022-02-20
Compared with patients aged 41-69 years, younger women had more grade III tumors (49% vs 35.
Compared with patients aged 41-69 years, younger women had more grade III tumors (49% vs 35.
-
For the treatment of brain metastases from breast cancer, which is stronger small molecule TKI vs macromolecule monoclonal antibody?
Time of Update: 2022-02-20
Recently, a study investigating the activity and safety of pyrotinib combined with capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases was published in THE LANCET ONCOLOGY.
-
Mechanism of Infiltration Barrier in Transforming "Cold Tumor" into "Hot Tumor" by Improving T Cell Infiltration (1)
Time of Update: 2022-02-20
This result suggests that activation of Wnt/β-catenin signaling and deficient BATF3 DCs mediate T cell rejection and tumor cell escape from the immune system .
In a mouse melanoma model, A2AR inhibition increased T lymphocyte infiltration and resulted in improved tumor control, suggesting a potential role of ADO signaling in promoting T cell rejection .
-
J Clin Oncol: The addition of carboplatin or bevacizumab to neoadjuvant chemotherapy for triple-negative breast cancer does not improve long-term outcomes (LTOs)
Time of Update: 2022-02-20
The aim was to investigate whether the addition of carboplatin or bevacizumab to weekly paclitaxel (wP) in combination with AC (doxorubicin and cyclophosphamide) significantly improved pathological complete responses in stage II-III triple-negative breast cancer ( pCR) rate and improve long-term outcomes (LTOs) of patients .
-
Clin Cancer Res: Cabozantinib Monotherapy for Advanced Soft Tissue Sarcoma
Time of Update: 2022-02-20
High levels of activated MET receptors have been reported in various sarcoma cell lines, coupled with elevated vascular endothelial growth factor (VEGF) levels in patients with STS, suggesting the use of the multi-receptor tyrosine kinase inhibitor cabozantinib Dual targeting of the VEGF and MET pathways by nisin would yield clinical benefit in this population .
-
CDK4/6: New insights into old targets
Time of Update: 2022-02-20
▎WuXi AppTec's content team edits the role of CDK4/6 in promoting cell cycle progression.
Today, the WuXi AppTec content team will share some of the wonderful content with readers,
-
NEJM: Cardiovascular disease and cancer risk in tofacitinib-treated rheumatoid arthritis patients
Time of Update: 2022-02-20
Combining doses of tofacitinib with a TNF inhibitor was compared in a population at cardiovascular risk, with a higher risk of MACE and cancer in the tofacitinib group and some adverse events more frequently with tofacitinib .
-
Quit drinking always quit?
Time of Update: 2022-02-19
Chile and Brazil recently described the alcohol-induced cancer burden:In both countries,Alcohol consumption is estimated to be the third preventable cause of cancer morbidity and mortality, accounting for 3.
-
BMC Cancer: Baseline Serum Cholinesterase (ChE) as an Independent Prognostic Indicator in Patients with Non-Small Cell Lung Cancer (NSCLC)
Time of Update: 2022-02-19
Studies have shown that baseline serum cholinesterase (ChE) can be used as an independent prognostic indicator in patients with non-small cell lung cancer (NSCLC) .
Studies have shown that baseline serum cholinesterase (ChE) can be used as an independent prognostic indicator in patients with non-small cell lung cancer (NSCLC) .
-
Cancers: Efficacy of conventional therapy (CT, chemotherapy with or without targeted therapy) after treatment failure in dMMR/MSI metastatic colorectal cancer (mCRC)
Time of Update: 2022-02-19
Mismatch repair deficient/microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) with immune checkpoint inhibitor (ICI) progression followed by conventional therapy (CT, chemotherapy with or without targeted therapy) efficacy is unclear .
-
Imaging Collection: One sentence makes it easy for you to learn imaging diagnosis
Time of Update: 2022-02-19
Secondly, the tympanic membrane can also be blue when there is a fracture of the temporal bone and blood in the tympanic cavity .
The X-ray characteristics of acute osteomyelitis of long bones are: one viscera, two destructions, three living chun; and sequestrum in the heel .
-
Imfinzi in combination with tremelimumab shows OS-prolonging benefit in liver cancer
Time of Update: 2022-02-19
AstraZeneca recently announced more results from the Phase III HIMALAYA study, saying the addition of tremelimumab to its PD-L1 blocker Imfinzi (durvalumab) reduced the risk of death by 22% in patients with unresectable liver cancer .
-
Eur Urol Oncol: Intravesical VPM1002BC for non-muscle-invasive bladder cancer (NMIBC) recurrence after conventional BCG therapy
Time of Update: 2022-02-19
Recently, researchers from Switzerland published an article in "Eur Urol Oncol" to investigate the efficacy, safety, tolerability and efficacy of intravesical injection of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer (NMIBC) following conventional BCG therapy.
-
Towards precision and intelligence, minimally invasive surgery adds value to the treatment of early-stage lung cancer
Time of Update: 2022-02-19
At the launching ceremony, Shan Yong, Vice President of Medtronic Innovative Surgery China, said: " In addition to providing surgeons with various surgical tools, Medtronic Innovative Surgery has been committed to breaking through industry boundaries around major diseases, building a diagnosis and treatment ecosystem, and improving patients.
-
Front Oncol: Characteristics and clinical prognosis of EGFR-mutant NSCLC with meningeal metastasis (LM)
Time of Update: 2022-02-19
Taken together, the study showed that osimertinib treatment had better clinical outcomes in patients with EGFR-mutant NSCLC after diagnosis of LM .
Taken together, the study showed that osimertinib treatment had better clinical outcomes in patients with EGFR-mutant NSCLC after diagnosis of LM .
-
Front Oncol: EGFR-TKI combined with thymosin in the treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC) improves patient outcomes
Time of Update: 2022-02-19
Recently, a team from Xinqiao Hospital of Chongqing Military Medical University has carried out related research, mainly to explore the efficacy and safety of EGFR-TKI combined with thymosin in the treatment of advanced non-small cell lung cancer ( NSCLC ) patients with EGFR mutations .
-
Molecular Cancer: First clinical trial: salivary exosomal small RNAs as esophageal cancer detection and prognostic markers
Time of Update: 2022-02-19
Collectively, this prospective clinical study showed that a dual signature composed of two small RNAs, tRNA-GlyGCC-5 and sRESE, could serve as a non-invasive biomarker for the diagnosis and prognosis of esophageal squamous cell carcinoma (ESCC) , It is also possible to determine which patients may benefit from adjuvant therapy prior to surgery .
-
Eur Urol Focus: What are the long-term outcomes of thulium laser enucleation of the prostate?
Time of Update: 2022-02-19
Durability of ThuLEP efficacy was demonstrated by investigating long-term efficacy and morbidityThe study included all patients treated with ThuLEP at a tertiary referral center in Germany between 2009 and 2021, who were retrospectively followed to investigate whether prostate adenoma persisted, re-grown (ReIP), or had long-term complications.
-
Cell: Heavy!
Time of Update: 2022-02-18
In a new study published in Cell in the early morning of January 20, Beijing time , a research team from the University of Basel in Switzerland found that T cells can effectively eliminate abnormal or infected cells only in a magnesium-rich environment.
-
Nature Med: Combination of GD2 and CD47 antibody drug shows broad-spectrum anti-cancer potential
Time of Update: 2022-02-18
Majzner, Stanford University Nature Medicine Nature Medicine Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication Antitumor activity has been shown in multiple preclinical models including neuroblastoma, osteosarcoma, and small cell lung cancer .